Teleflex Announces Third Quarter 2026 Earnings Conference Call
Teleflex Incorporated has scheduled its third quarter 2026 financial results conference call for November 5, 2026.
Stocks · News reference
Teleflex Receives FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
The U.S. Food and Drug Administration has granted Breakthrough Device Designation to Teleflex's Freesolve™ Resorbable Magnesium Scaffold for use in percutaneous coronary intervention.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Teleflex Receives FDA Breakthrough Device Designation For Its Freesolve Resorbable Magnesium Scaffold For Percutaneous Coronary Intervention
Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $142
Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:TFX) with a Hold and lowers the price target from $150 to $142.